NASDAQ: DNTH Dianthus Therapeutics, Inc. /DE/ 8-K

Dianthus wins FDA approval to remove lupus screening from claseprubart trials

Filed March 26, 2026 · Period ending March 26, 2026 · ~1 min read

4 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade DNTH commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 4, 2026 3:16 AM